Mash Cirrhosis

Bariatric surgery was associated with improved survival and appeared cost-effective over 10 years among patients with obesity and compensated cirrhosis, according to an analysis published in JAMA Surgery.

PHILADELPHIA — In this video, Paul Kwo, MD, professor of medicine and director of hepatology at Stanford University, discusses data from the ongoing MAESTRO-NASH trial, which were presented at the ACG Annual Scientific Meeting.

Madrigal Pharmaceutical’s Rezdiffra received accelerated FDA approval for the treatment of patients with metabolic dysfunction-associated steatohepatitis with moderate-to-advanced fibrosis, according to a company release.

Topline findings from a phase 2 trial showed that survodutide achieved “statistically significant improvement” for metabolic dysfunction-associated steatohepatitis and liver fibrosis in 83% of patients, Boehringer Ingelheim announced.